Novartis developed the therapy under a research partnership with Astex Pharmaceuticals. Credit: © 2024 Novartis AG.

The European Commission (EC) has granted approval to Novartis‘ Kisqali (ribociclib), plus an aromatase inhibitor to treat early breast cancer patients.

The combination is intended for the adjuvant treatment of high-risk, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The EC’s decision stems from the outcomes of the pivotal global Phase III NATALEE trial, which evaluated the safety and efficacy of Kisqali plus endocrine therapy against endocrine therapy alone in subjects with stage II and III HR+/HER2- early breast cancer.

The trial comprised 5,101 subjects across 20 countries. It demonstrated a 25.1% decrease in the disease recurrence risk, with the invasive disease-free survival (iDFS) benefit observed to be consistent across all subject subgroups.

The primary endpoint was iDFS as defined by the Standardized Definitions for Efficacy End Points (STEEP) criteria.

The EC approval follows the US Food and Drug Administration’s recent approval of Kisqali for the same indication.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology also recommended the therapy as a Category 1 preferred adjuvant treatment for breast cancer.

Novartis developed the therapy under a research partnership with Astex Pharmaceuticals.

Novartis Europe president Iris Zemzoum stated: “Breast cancer recurrence can be a lifelong concern for those living with the disease. Patients deserve access to treatment options that help minimise the risk of their cancer coming back and put their minds at ease.

“We are proud of this approval, which will help to address a key unmet need and improve health outcomes for a broader population of patients in Europe.”

The company’s recent development includes the acquisition of San Diego-based Kate Therapeutics in a $1.1bn deal.